Investors with substantial losses have opportunity to lead class action lawsuit against ImmunityBio.
San Diego Today
Robbins Geller Rudman & Dowd LLP has announced a deadline for investors who purchased or acquired ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026 to join a class action lawsuit. The lawsuit alleges that ImmunityBio made false claims about its cancer treatment Anktiva.
This lawsuit represents a significant legal challenge for ImmunityBio, a prominent biotech company, and could have major financial and reputational implications if the allegations are proven true. The outcome of the case could impact investor confidence in ImmunityBio and the broader biotech industry.
The lawsuit alleges that ImmunityBio made misleading statements about its Anktiva cancer treatment, claiming it would allow all non-muscle-invasive bladder cancer (NMIBC) patients to be cancer-free long-term, when this had not been demonstrated. The lawsuit claims these false statements artificially inflated ImmunityBio's stock price during the class period.
A law firm that specializes in securities class action lawsuits and has announced the ImmunityBio investor lawsuit.
A biotechnology company...
The government is moving to reassure sugarcane farmers and counter misinformation, confirming that its financial support for the 2025 crop season remains intact and properly calculated. Minister f...